Ladarixin, an inhibitor of the interleukin‐8 receptors CXCR1 and CXCR2, in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled trial

por Piemonti, Lorenzo, Keymeulen, Bart, Gillard, Pieter, Linn, Thomas, Bosi, Emanuele, Rose, Ludger, Pozzilli, Paolo, Giorgino, Francesco, Cossu, Efisio, Daffonchio, Luisa, Goisis, Giovanni, Ruffini, Pier Adelchi, Maurizi, Anna Rita, Mantelli, Flavio, Allegretti, Marcello
Publicado 2022